Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, Novem...
October 29 2020 - 4:01PM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced that the company will host a webinar focused on its
pyruvate kinase-R (PKR) activation clinical programs and the
commercial outlook across three distinct hemolytic anemias on
Thursday, November 19, 2020 from 8:00 a.m. to 10:30 a.m. ET.
The webinar will provide an overview of Agios’ leadership in
elucidating the PKR activation mechanism; the role of PKR
activators in treating serious hemolytic anemias, including
pyruvate kinase (PK) deficiency, thalassemia and sickle cell
disease, as evidenced by significant clinical data across these
three disease areas; and the company’s commercial outlook and
preparations for its first potential launch in a rare genetic
disease. Presentations will be given by members of Agios’
leadership team and external speakers including:
- Eduard J. van Beers, M.D., Ph.D., hematologist and associate
professor at University Medical Center Utrecht
- Jackie Fouse, Ph.D., chief executive officer at Agios
- Chris Bowden, M.D., chief medical officer at Agios
- Bruce Car, Ph.D., chief scientific officer at Agios
- Darrin Miles, senior vice president U.S. commercial and global
marketing at Agios
A live webcast of the presentations can be accessed under
"Events & Presentations" in the Investors section of the
company's website at www.agios.com. The presentations are scheduled
to begin at 8:00 a.m. ET and conclude at 10:30 a.m. ET. A replay of
the webcast will be archived on the Agios website for at least two
weeks following the presentation.
About AgiosAgios is focused on discovering and
developing novel investigational medicines to treat malignant
hematology, solid tumors and rare genetic diseases through
scientific leadership in the field of cellular metabolism. In
addition to an active research and discovery pipeline across these
three therapeutic areas, Agios has two approved oncology precision
medicines and multiple first-in-class investigational therapies in
clinical and/or preclinical development. For more information,
please visit the company's website at www.agios.com.
Contacts
Investors:Holly Manning, 617-844-6630Director,
Investor RelationsHolly.Manning@agios.com
Media:Jessica Rennekamp, 857-209-3286Associate
Director, Corporate CommunicationsJessica.Rennekamp@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024